Quintrio
Home

MEASURING & CONTROLLING DEVICES, NEC

Thermo Fisher Scientific, Inc.

TMO

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Last trade $689.35
Day change -$1.985 (-0.29%)
Day range $683.29 – $694.97
Volume 650,332
Market cap $256.15B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$256.15B
Price / earnings
36.22×
Price / book
4.68×
Price / sales
5.41×
EV / sales
6.17×
EV / EBITDA
24.4×

Profitability

Earnings per share
$19.09
Return on assets
6.19%
Return on equity
12.91%
Dividend yield
0.26%

Liquidity and leverage

Debt / equity
0.76×
Current ratio
1.81×
Quick ratio
1.41×
Cash ratio
0.39×

Cash flow

Price / cash flow
27.47×
Price / free cash flow
33.72×
Free cash flow
$7.6B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TMO, quarterly periods
Line itemQ3 FY2026 Sep 26, 2026Q2 FY2026 Jun 27, 2026Q1 FY2026 Mar 28, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 27, 2025Q2 FY2025 Jun 28, 2025Q1 FY2025 Mar 29, 2025Q4 FY2024 Dec 31, 2024
Revenue$12.14B$11.99B$11.01B$12.22B$11.12B$10.86B$10.36B$11.4B
Cost of revenue$7.01B$7.11B$6.58B$7.2B$6.54B$6.45B$6.13B$6.57B
Gross profit$5.13B$4.88B$4.43B$5.01B$4.58B$4.41B$4.24B$4.82B
Selling, general and administrative$2.32B$2.33B$2.18B$2.35B$2.16B$2.14B$2.08B$2.2B
Research and development$348M$364M$336M$356M$346M$352M$342M$374M
Total operating expenses$2.87B$2.8B$2.57B$2.76B$2.64B$2.58B$2.52B$2.81B
Operating income$2.26B$2.09B$1.86B$2.26B$1.94B$1.83B$1.72B$2.02B
Interest expense-$417M-$401M-$354M-$365M-$347M-$404M-$303M-$317M
Income before taxes$2.08B$1.91B$1.73B$2.15B$1.83B$1.71B$1.62B$1.94B
Income taxes$352M$167M$70M$153M$207M$92M$95M$150M
Net income$1.73B$1.74B$1.66B$1.97B$1.62B$1.62B$1.51B$1.82B
Net income attributable to common shareholders$1.72B$1.74B$1.65B$1.96B$1.62B$1.62B$1.51B$1.83B
EBITDA$4.2B$2.09B$2.65B$3.03B$3.6B$1.74B$2.52B$2.99B
Basic earnings per share$4.65$4.68$4.44$5.25$4.28$4.28$3.99$4.79
Diluted earnings per share$4.64$4.68$4.43$5.21$4.27$4.28$3.98$4.80

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott reported strong mid-to-high-teens EP sales growth globally and over 20% in the U.S., driven by accelerating Volt PFA catheter adoption following its August launch. The company received FDA approval for TactiFlex Duo and CE Mark for Amulet 360, expanding treatment options. However, LAA market weakness is creating headwinds as customers delay purchases awaiting the new Amulet 360 device. Abbott expects Japan's Q4 Volt launch to provide growth momentum.

GlobeNewswire Inc.

Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck

The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.

GlobeNewswire Inc.

Nucleic Acid Labeling - Global Strategic Business Report 2026: Secure Share of a $2.8 Billion Market by 2032 as Thermo Fisher Scientific, Roche, Merck, and Agilent Accelerate Genomics

The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.

Zacks Investment Research

If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now

A $1,000 investment in Thermo Fisher Scientific made in November 2016 would be worth $4,734.73 as of November 2, 2026, representing a 373.47% gain that significantly outperformed the S&P 500's 256.47% return. The company benefits from recovering pharma and biotech spending, expanded capabilities through acquisitions, and AI-enabled workflows, though academic spending remains subdued and competition poses ongoing challenges.

Zacks Investment Research

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus

Zacks highlights strong stock performance across its various investment portfolios in early November 2026. Marathon Petroleum gained 14.71% following a Zacks Rank upgrade, while Chevron and Cheniere Energy surged 22.5% and 28% respectively over 12 weeks. Amgen returned 20.2% over the same period as investors favor quality dividend stocks amid market volatility. The article showcases performance of Zacks' rating systems including the Rank #1 portfolio, Focus List, and specialized portfolios like ECAP and ECDP.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.47 per share
Declared
Nov 5, 2026
Ex-dividend
Dec 15, 2026
Pay date
Jan 15, 2027
Ex-dividendAmount / sharePay dateType
Sep 15, 2026$0.47Oct 15, 2026recurring
Jun 15, 2026$0.47Jul 15, 2026recurring
Mar 13, 2026$0.47Apr 15, 2026recurring
Dec 15, 2025$0.43Jan 15, 2026recurring
Sep 15, 2025$0.43Oct 15, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.